PT  - JOURNAL ARTICLE
AU  - Mistry, Akshitkumar M.
AU  - Naidugari, Janki
AU  - Feldman, Michael J.
AU  - Magarik, Jordan A.
AU  - Ding, Dale
AU  - Abecassis, Isaac J.
AU  - Semler, Matthew W.
AU  - Rice, Todd W.
TI  - Impact of Fludrocortisone on the Outcomes of Subarachnoid Hemorrhage Patients: A Retrospective Analysis
AID  - 10.1101/2023.09.28.23296246
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.09.28.23296246
4099  - http://medrxiv.org/content/early/2023/09/29/2023.09.28.23296246.short
4100  - http://medrxiv.org/content/early/2023/09/29/2023.09.28.23296246.full
AB  - Background Whether the use of fludrocortisone affects outcomes of patients with aneurysmal subarachnoid hemorrhage (aSAH) and its usage rate in the United States remain unknown.Methods We conducted a retrospective analysis of 78 consecutive patients with a ruptured aSAH at a single academic center in the United States. The primary outcome was the score on the modified Rankin scale (mRS, range, 0 [no symptoms] to 6 [death]) at 90 days. We adjusted the primary outcome for age, hypertension, aSAH grade, and time from aSAH onset to aneurysm treatment. Secondary outcomes were brain and cardiopulmonary dysfunction events.Results Among 78 patients at a single center, the median age was 58 years [IQR, 49 to 64.5]; 64% were female, and 41 (53%) received fludrocortisone. The adjusted common odds ratio, aOR, of a proportional odds regression model of fludrocortisone use with mRS was 0.33 (95% CI, 0.14-0.80; P=0.02), with values <1.0 favoring fludrocortisone. Organ-specific dysfunction events were not statistically different: delayed cerebral ischemia (22% vs. 39%, P=0.16); cardiac dysfunction (0% vs. 11%; P=0.10); and pulmonary edema (15% vs. 8%; P=0.59).Conclusions The risk of disability or death at 90 days was lower with the use of fludrocortisone in aSAH patients.Competing Interest StatementIsaac Abecassis has the following disclosures: 1) Remedy Robotics: Consultant, Equity. 2) IschemaView Inc/Rapid AI: Clinical consultant. 3) Rapid Medical: Consultant. 4) Balt: Consultant. 5) CNS Foundation: Grant Research Support.Funding StatementThis study was funded by the Vanderbilt Institute for Clinical and Translational Research (UL1TR000445 and UL1TR002243 from NCATS/NIH).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Vanderbilt University Medical Center gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors